Kim Jean Jinsun 4
4 · Avidity Biosciences, Inc. · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
Avidity (RNAM) Director Kim Jean Jinsun Sells Shares in Merger
What Happened
Director Kim Jean Jinsun disposed of a total of 104,215 shares and option-equivalents on 2026-02-27 pursuant to Avidity’s Merger Agreement with Novartis. The merger consideration was $72.00 per share. The reported disposals include 6,692 shares of common stock (including RSUs) and 97,523 derivative units (options and/or other derivatives). Common stock/RSUs were exchanged at $72 per share; reported options were cashed out for the difference between the $72 merger price and each option’s exercise price. If every unit were paid at $72 the notional amount would be about $7.50 million, though actual option payouts equal only the spread over strike prices.
Key Details
- Transaction date: 2026-02-27 (all reported dispositions). Merger consideration: $72.00 per share.
- Dispositions: six entries totaling 104,215 total units (6,692 common stock/RSU; 97,523 derivative instruments).
- Shares owned after the transactions: not specified in the provided Form 4 details.
- Footnotes: F1 — disposals pursuant to the Agreement and Plan of Merger dated Oct 25, 2025 (Novartis acquisition). F2 — options were cashed out for the excess of $72 over the exercise price.
- Filing timeliness: Form filed 2026-02-27 (same date as report), indicating a timely report.
Context
These transactions were executed under the terms of the Novartis acquisition of Avidity and reflect merger consideration and option cash-outs rather than open-market trading. Disposals tied to a corporate transaction like a merger are common and follow deal terms (not necessarily a personal trading decision).
Insider Transaction Report
- Disposition to Issuer
Common Stock
[F1]2026-02-27−6,692→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
[F2]2026-02-27−10,034→ 0 totalExercise: $33.62Exp: 2035-06-09→ Common Stock (10,034 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
[F2]2026-02-27−13,489→ 0 totalExercise: $39.96Exp: 2034-06-12→ Common Stock (13,489 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
[F2]2026-02-27−22,000→ 0 totalExercise: $12.48Exp: 2033-06-14→ Common Stock (22,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
[F2]2026-02-27−22,000→ 0 totalExercise: $12.03Exp: 2032-06-14→ Common Stock (22,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
[F2]2026-02-27−30,000→ 0 totalExercise: $27.63Exp: 2031-01-10→ Common Stock (30,000 underlying)
Footnotes (2)
- [F1]The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
- [F2]The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.